AMVUTTRA® (vutrisiran) is now listed on the Pharmaceutical Benefits Scheme (PBS) for eligible Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy [1]
1 May 2025. Medison Pharma Australia Pty Ltd (“Medison Pharma”), alongside their partner Alnylam Pharmaceuticals, Inc. (“Alnylam”), is pleased to announce that from 1 May 2025, AMVUTTRA® (vutrisiran) is listed on the Pharmaceutical Benefits Scheme (PBS) for hereditary transthyretin-mediated amyloidosis in adult patients, with stage 1 or stage 2 polyneuropathy, confirmed by genetic testing.1,2,3 Hereditary […]
Medison Pharma and Immunocore Announce ANVISA Approval of KIMMTRAK® (tebentafuspe) for the Treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma in Brazil[1]
KIMMTRAK (tebentafuspe) is the first and only approved treatment for Brazilian adult patients living with this disease SÃO PAULO, Brazil – [March 18th, 2025]: Medison Pharma, a global company focused on accelerating access to highly innovative therapies in international markets, and Immunocore Holdings plc (NASDAQ: IMCR), a commercial-stage biotechnology company focused on pioneering and […]
PBS listing for Australians with hereditary transthyretin-mediated amyloidosis with polyneuropathy[1]
Sydney, Thursday 1 August, 2024. Medison Pharma, alongside their partner Alnylam Pharmaceuticals, Inc., are pleased to announce that from 1 August 2024, ONPATTRO® (patisiran) is listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients, with stage 1 or stage 2 polyneuropathy, confirmed by genetic testing. […]
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of Alnylam’s innovative RNAi technologies ZUG, Switzerland, April 30, 2024 /PRNewswire/ — Medison Pharma (“Medison”), a global pharma company focused on providing access to […]
PBS listing for Australians with unresectable or metastatic uveal melanoma
Sydney, Thursday 1 February, 2024. Medison Pharma, alongside their partner Immunocore Holdings Ltd (NASDAQ: IMCR), is pleased to announce that from today KIMMTRAK® (tebentafusp) is listed on the Pharmaceutical Benefits Scheme (PBS) for the treatment of HLA-A*02:01-positive adult patients with advanced (unresectable or metastatic) uveal melanoma who have not previously received systemic treatment.1,[2],[3] Uveal […]
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory authorities in more than two dozen countries for various indications Medison and Regeneron will work […]
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition ZUG, Switzerland and PARIS, Nov. 13, 2023 /PRNewswire/ — Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience, and Medison Pharma (“Medison”), a global pharma company focused on providing access to highly […]
Alnylam Pharmaceuticals and Medison Pharma Announce the Expansion of Their Collaboration to a Multi-Regional Partnership to Commercialize RNAi Therapeutics
ZUG, Switzerland March 9, 2023/ (NEWSWIRE)/Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, […]
Sarah Otten Joins Medison Pharma as VP, GM Americas Region
PETACH TIKVAH, Israel and ZUG, Switzerland, Jan. 9, 2023 /PRNewswire/ — Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in international markets (“Medison”), is proud to announce the joining of Sarah Otten, in the role of VP, GM of Medison’s Americas Region. Sarah Otten Joins Medison Pharma as VP, GM Americas Region (Photo […]
Medison Pharma Announces Expansion of the Multi-Territorial Agreement with Immunocore into Latin America
PETACH TIKVAH, Israel, Nov. 9, 2022 /PRNewswire/ — Medison Pharma (“Medison”), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, today announced the addition of South and Central America and the Caribbean markets (“Latin America“) to its multi-territorial agreement with Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore”), a commercial-stage biotechnology company pioneering the development of a novel class […]